The scheme applies to originator pharmaceuticals that have limited chances of obtaining a positive reimbursement status based on their list price.
- With the new law, citizens will gain access to pharmaceuticals that they would otherwise not be able to purchase with a subsidy. This is conditional upon companies being able to offer a sufficiently low price. We look forward to this task with great anticipation and are confident that it will benefit patients, companies, and the public sector alike, says Flemming Sonne, CEO of Amgros.
It’s not only the public who will benefit from the new scheme - companies also stand to gain. With Amgros now able to negotiate confidential prices on pharmaceuticals with limited reimbursement prospects based on list prices, this opens a new path for companies to achieve a positive reimbursement status. This will likely lead to increased sales, as more patients will be able to purchase the pharmaceuticals at pharmacies.
Once Amgros has reached a negotiated price with the originator company, a body appointed by the regions will assess whether the confidential price can proceed to a reimbursement evaluation. Amgros will serve as the secretariat for this body.
Finally, the new scheme is also advantageous for the regions, providing them with another tool to manage public spending on pharmaceutical subsidies - which rose by 16.4% from 2022 to 2024.
- Amgros looks forward to getting started and hopes that many companies will take advantage of the pilot scheme. We expect to launch after the summer and will work together with the companies to find the best solutions to the many details this new type of negotiation brings, says Flemming Sonne.
From July 1, 2025, it will be possible to apply for general or generally conditional reimbursement based on a confidential price through the Danish Medicines Agency. The confidential price is negotiated between Amgros and the original manufacturer of a pharmaceutical.
Negotiation of confidential prices within the reimbursement system will be relevant for original manufacturers of pharmaceuticals that are either: 1) a new and expensive pharmaceutical, 2) a pharmaceutical undergoing a reassessment of its subsidy status, or 3) a pharmaceutical being transferred from hospital treatment to the primary care sector.
A comprehensive guide will soon be available on Amgros’ website.
Contact
Søs Nielsen
Senior Advisor
I work with cross-functional development initiatives, particularly with negotiations of confidential prices for the primary sector and follow-up on our alternative agreements.
Karen Torgny
Senior Specialist- Communication
I’m responsible for overall communication at Amgros, including PR. And I help to ensure that we communicate with the surrounding world in an open and engaging manner.
Â